Zacks: Analysts Anticipate Seres Therapeutics Inc (NASDAQ:MCRB) to Announce -$0.26 EPS

Equities research analysts expect Seres Therapeutics Inc (NASDAQ:MCRB) to post ($0.26) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Seres Therapeutics’ earnings, with estimates ranging from ($0.30) to ($0.22). Seres Therapeutics reported earnings per share of ($0.52) in the same quarter last year, which would indicate a positive year-over-year growth rate of 50%. The firm is expected to report its next quarterly earnings results on Wednesday, March 4th.

On average, analysts expect that Seres Therapeutics will report full year earnings of ($1.26) per share for the current year, with EPS estimates ranging from ($1.37) to ($1.20). For the next financial year, analysts anticipate that the company will post earnings of ($0.78) per share, with EPS estimates ranging from ($0.95) to ($0.51). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Seres Therapeutics.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.23) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.26) by $0.03. The business had revenue of $7.03 million for the quarter, compared to analyst estimates of $6.69 million.

MCRB has been the subject of a number of recent research reports. BidaskClub cut shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 31st. HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Seres Therapeutics in a research report on Thursday, November 21st. ValuEngine upgraded shares of Seres Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, January 3rd. Cowen restated a “buy” rating on shares of Seres Therapeutics in a research report on Monday, November 4th. Finally, Zacks Investment Research downgraded shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 29th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Seres Therapeutics presently has an average rating of “Buy” and a consensus target price of $7.75.

NASDAQ:MCRB traded down $0.05 during trading hours on Friday, reaching $3.43. 265,155 shares of the company’s stock were exchanged, compared to its average volume of 218,759. The firm has a market capitalization of $243.64 million, a price-to-earnings ratio of -2.17 and a beta of 1.78. The company has a 50-day moving average of $3.74 and a 200 day moving average of $3.47. Seres Therapeutics has a 1-year low of $2.02 and a 1-year high of $8.39.

A number of institutional investors have recently made changes to their positions in the business. Squarepoint Ops LLC purchased a new position in Seres Therapeutics during the 3rd quarter worth $215,000. Barclays PLC raised its position in Seres Therapeutics by 36.5% during the 3rd quarter. Barclays PLC now owns 19,737 shares of the biotechnology company’s stock worth $79,000 after buying an additional 5,278 shares during the last quarter. California State Teachers Retirement System raised its position in Seres Therapeutics by 72.3% during the 3rd quarter. California State Teachers Retirement System now owns 56,844 shares of the biotechnology company’s stock worth $228,000 after buying an additional 23,862 shares during the last quarter. State Street Corp raised its position in Seres Therapeutics by 24.9% during the 3rd quarter. State Street Corp now owns 573,351 shares of the biotechnology company’s stock worth $2,299,000 after buying an additional 114,375 shares during the last quarter. Finally, Voya Investment Management LLC raised its position in Seres Therapeutics by 35.1% during the 3rd quarter. Voya Investment Management LLC now owns 13,670 shares of the biotechnology company’s stock worth $55,000 after buying an additional 3,555 shares during the last quarter. Institutional investors own 91.86% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).

See Also: Analyst Ratings Trading

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.